Free Trial

Sage Therapeutics (SAGE) Earnings Date, Estimates & Call Transcripts

Sage Therapeutics logo
$8.68 0.00 (0.00%)
As of 07/31/2025

Sage Therapeutics Earnings Summary

Sage Therapeutics issued Q2 2025 earnings on July 30, 2025, reporting an EPS of -$0.79, which beat analysts' consensus estimates of -$0.96 by $0.17. Quarterly revenue rose 266.0% year-over-year to $31.66 million, above the consensus estimate of $16.69 million. With a trailing EPS of -$4.89, Sage Therapeutics' earnings are expected to grow next year, from ($3.52) to ($2.52) per share.

Latest Q2
Earnings Date
Jul. 30Estimated
Consensus EPS
(Jul. 30)
-$0.96
Actual EPS
(Jul. 30)
-$0.79 Beat By $0.17
Actual Revenue
(Jul. 30)
$31.66M

Q2 2025 Earnings Resources

Get Sage Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sage Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

SAGE Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SAGE Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Sage Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20254-$1.64-$1.03-$1.24
Q2 20254-$1.56-$0.94-$1.12
Q3 20254-$1.55-$0.15-$0.87
Q4 20254-$1.54-$0.86-$1.06
FY 2025 16 -$6.29 -$2.98 -$4.28
Q1 20262-$0.82-$0.65-$0.74
Q2 20262-$0.84-$0.63-$0.74
Q3 20262-$0.68-$0.60-$0.64
Q4 20262-$0.68-$0.55-$0.62

Sage Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025-$0.96-$0.79+$0.17-$0.79$16.69M$31.66M
4/29/2025Q1 2025-$0.99-$1.01 -$0.02-$1.01$14.12M$14.06M
2/11/2025Q4 2024-$1.54-$1.56 -$0.02-$1.56$14.37M-
10/29/2024Q3 2024-$1.52-$1.53 -$0.01-$1.53$10.80M$11.87M
7/31/2024Q2 2024-$1.68-$1.70 -$0.02-$1.70$8.85M$8.65M
4/25/2024Q1 2024-$1.63-$1.80 -$0.17-$1.80$5.26M$7.90M
2/14/2024Q4 2023-$1.28-$0.55+$0.73-$0.55$60.15M$77.97M
11/7/2023Q3 2023-$2.64-$2.81 -$0.17-$2.25$9.02M$2.72M

Sage Therapeutics Earnings - Frequently Asked Questions

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earning data on Wednesday, July 30, 2025. Learn more on SAGE's earnings history.

In the previous quarter, Sage Therapeutics (NASDAQ:SAGE) reported ($0.79) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.96) by $0.17. Learn more on analysts' earnings estimate vs. SAGE's actual earnings.

Sage Therapeutics (NASDAQ:SAGE) has a recorded annual revenue of $41.24 million.

Sage Therapeutics (NASDAQ:SAGE) has a recorded net income of -$400.67 million. SAGE has generated -$4.89 earnings per share over the last four quarters.

Sage Therapeutics' earnings are expected to grow from ($3.52) per share to ($2.52) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:SAGE) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners